Description: Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Home Page: www.acastipharma.com
103 Carnegie Center
Princeton,
NJ
08540
United States
Phone:
818 839 4378
Officers
| Name | Title |
|---|---|
| Mr. Prashant Kohli | CEO & Director |
| Mr. Amresh Kumar Ph.D. | VP of Program Management |
| Ms. Carrie D'Andrea | VP of Clinical Operations |
| Mr. Robert J. DelAversano CPA | VP of Finance and Principal Financial & Accounting Officer |
| Dr. R. Loch MacDonald M.D., Ph.D. | Member of Scientific Advisory Board & Chief Medical Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2024-10-08 |
| Fiscal Year End: | March |
| Full Time Employees: | 0 |